RE: nice start eom
One of the primary keys to us seeing higher volume and wider recognition of the underlying value here is the work of Corporate IR...
The lack of reaction to the unexpectedly good preliminary 1402 results (although bungled ) and the lack of respect given to the impending MacoPharma /PRDT initiatives is in my eyes a direct failure of IR communication with Analysts and Institutions to get the depth of the true story out to the right people.
I understand that we are paying for damage done in the past and the IR team is new and doing alot of damage control... But, if the story is truly as compelling as we all see it to be, how hard of a sell can this really be !? Where's the new analyst coverage ? Analalysts are always looking to be hero's by uncovering " the next one " Instead we are saddled by amateurish uninformed damaging coverage ( except maybe Loewens )
We constantly hear about the depth of understanding of the BSE blood safety issue in Europe, where's the European institutional buying ? Where's ANY institutional buying ? They certainly were in between a $1.0 and $1.50 ... where are they now ? IF there's so much here, why arent they backing up the perverbial truck..... ?
There's two potential answers, there's less here than we think OR the message isnt getting out effectively to the right people. The fact is, the INDUSTRY is endorsing this company in SPADES.... big name BIO and Pharma are all over the technology...... the industry is convinced.... as evidenced by multitude of solid contracts.....why isnt the invesment community convinced ?? Bottom line, the job's still not getting done as effectively as it needs to be and I still dont think management understands the importance of this and prioritizing appropriately. WE NEED PROFILE to get RESPECT